Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
David Henry MD

David Henry MD

Vice Chair, Department of Medicine; Clinical Professor of Medicine (Hematology-Oncology), Pennsylvania Hospital, Philadelphia, Pennsylvania

Dr. David Henry is Vice Chair of the Department of Medicine and  Clinical Professor of Hematology-Oncology at Pennsylvania Hospital in Philadelphia.

Dr. Henry was awarded his medical degree from the University of Pennsylvania School of Medicine, where he also completed resident and fellowship training.

In addition to his clinical responsibilities, Dr. Henry is a member of the American Board of Internal Medicine’s Subspecialty SEP Board of Hematology and a principal investigator for the Eastern Cooperative Oncology Group, Accelerated Community Oncology Research Network, and International Oncology Network research groups. His main interests for publication and research are anemia and neutropenia in oncology.

He is the Editor-in-Chief of MDEDGE.com/hematology-oncology and a reviewer for The New England Journal of Medicine, Journal of Clinical Oncology, Archives of Internal Medicine, and The Oncologist. He is also the author of a weekly podcast titled Blood and Cancer on iTunes.

Dr. Henry is a past winner of the annual Blockley-Osler Award for teaching at the University of Pennsylvania School of Medicine and is the director of the University of Vienna medical student exchange program in Philadelphia.

Recent Contributions to PracticeUpdate:

  1. 2024 Top Story in Oncology: Myeloma and Bispecific Antibodies
  2. Amivantamab Plus Lazertinib vs Osimertinib for First-Line EGFR-Mutant Advanced NSCLC With Biomarkers of High-Risk Disease
  3. Amivantamab Plus Lazertinib for Previously Untreated EGFR-Mutated Advanced NSCLC
  4. ASCO 2024: Abstract Recommendations From Dr. David Henry
  5. CNS Efficacy of Osimertinib With or Without Chemotherapy in Patients With EGFR-Mutated Advanced NSCLC
  6. 2023 Top Story in Oncology: Circulating Tumor DNA Analysis to Guide Adjuvant Therapy
  7. ESMO 2023: Recommendations From Dr. David Henry for General Oncology
  8. Nivolumab Plus Brentuximab Vedotin for Low-Risk Relapsed Classic Hodgkin Lymphoma
  9. Circulating Tumor DNA Following Neoadjuvant Chemotherapy and Surgery in ER-Positive and HER2-Negative Breast Cancer
  10. Neoadjuvant Chemoradiation for Treatment of LARC

Elsewhere

Most Read This Week

Recently Updated